Drug Trial Radar · NCT07559474
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
Last checked: Nov 20, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
May 27, 2026
Primary completion
Apr 13, 2027
Study completion Apr 13, 2027
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Apr 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with moderate or severe hepatic impairment.
Conditions
- Hepatic Insufficiency
- Liver Diseases
Interventions
INCB123667Drug
single dose administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK for plasma INCB123667: CmaxTime frame: Up to approximately 2 months
- PK for plasma INCB123667: AUCtTime frame: Up to approximately 2 months
- PK for plasma INCB123667: AUC∞Time frame: Up to approximately 2 months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Arizona Clinical Trials - the Institute For Liver Health
Chandler, Arizona · Recruiting
Orlando Clinical Research Center
Orlando, Florida · Recruiting
Texas Liver Institute - American Research Corporation
San Antonio, Texas · Recruiting
Pinnacle Clinical Research
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.